54% ...

... of WellCare members have access to Remicade, a DMARD used to treat ulcerative colitis and other autoimmune diseases, on the specialty tier, with prior authorizaton or step therapy. 24% of formularies do not cover Remicade, which is known for its high cost, and only 6% place it on the preferred tier.